CBS 2019
CBSMD教育中心
English

动脉粥样硬化性心血管疾病

科研文章

荐读文献

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes The Year in Cardiovascular Medicine 2020: Coronary Prevention: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of coronary prevention is Professor Ramon Estruch, Dr Luis Ruilope, and Professor Francesco Cosentino. Mark Nicholls meets them Association Between Depressive Symptoms and Incident Cardiovascular Diseases Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER Trial The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Consensusolume 41, Issue 24, 21 June 2020, Pages 2313–2330

JOURNAL:Eur Heart J. Article Link

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

J Borén, MJ Chapman, RM Krauss et al. Keywords: low-density lipoprotein; ASCVD; statin; mechanisms

Full Text PDF